Showing results (141-150 of 180) with videos related to
Sort By:
Pageof 18
Blood|October 31, 2018
Subclonal <i>TP53</i> copy number is associated with prognosis in multiple myelomaVallari Shah, David C Johnson, Amy L Sherborne, et al.Insights Into Imaging|October 15, 2023
Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma studySam Keaveney, Alina Dragan, Mihaela Rata, et al.The Lancet. Haematology|October 19, 2019
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trialGraham H Jackson, Faith E Davies, Charlotte Pawlyn, et al.Blood|December 28, 2020
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data setAjai Chari, Mehmet Kemal Samur, Joaquin Martinez-Lopez, et al.British Journal of Haematology|February 8, 2019
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, Kara-Louise Royle, Sheila O'Connor, et al.Haematologica|February 9, 2019
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patientsJohn R Jones, Niels Weinhold, Cody Ashby, et al.Journal for Immunotherapy of Cancer|July 3, 2019
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21Louise M E Müller, Matthew Holmes, Joanne L Michael, et al.British Journal of Haematology|July 14, 2020
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trialGraham H Jackson, Charlotte Pawlyn, David A Cairns, et al.American Journal of Hematology|June 18, 2026
The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN)Heinz Ludwig, Evangelos Terpos, Francesca Gay, et al.Leukemia|January 2, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIAThierry Facon, Gordon Cook, Saad Z Usmani, et al.Pageof 18